Another Johnson & Johnson Veteran Joins! Major Personnel Change at Medical Device Giant

On September 17, 2025, according to Reuters, diabetes giant Insulet announced a major personnel appointment:Flavia Pease, former Vice President and Group Chief Financial Officer of Johnson & Johnson Medical Devices, will be appointed as the company's new Chief Financial Officer and Executive Vice President.Effective September 30, replacing Ana Maria Chadwick.

Flavia Pease worked at Johnson & Johnson for more than 20 years, holding several leadership positions related to its medical device business, and served as Vice President of Finance in its Janssen Pharmaceuticals division.

Source: Flavia Pease's LinkedIn account

It is worth mentioning that since April this yearAshley McEvoy, former Global Chairman of Johnson & Johnson Medical Technology, takes overSince becoming CEO of InsuletSeveral senior personnel from the Johnson team have already joined the company.

Two months after McEvoy took office, Lisa Blair Davis, a seasoned executive with 23 years of experience at Johnson & Johnson, also joined Insulet.Appointed as Senior Vice President and Chief Human Resources Officer.。

On August 25th, Insulet announced the promotion of former Chief Product and Customer Experience Officer Eric Benjamin toChief Operating Officer, and appointed Manoj Raghunandanan asRaghunandanan, the Chief Growth Officer, also comes from Johnson & Johnson, having held significant positions in the Johnson & Johnson Consumer Health division.

At the beginning of last month, Insulet delivered an impressive performance: revenue for the second quarter of 2025 reached $649.1 million, a year-over-year increase of 31%, surpassing the $600 million mark for the first time. The gross margin increased to 69.7%, and management raised the full-year revenue growth forecast to 24%-27%, indicating their confidence in the continued growth momentum.

In the past 52 weeks,Insulet's stock price surged 77.8%, significantly outperforming the market.The market value has reached 22.8 billion USD (approximately RMB).162.5 billion24 stock analysts unanimously rated it as a "strong buy."

Not long ago, Newsweek collaborated with the data company Plant A to release...The list of the greatest companies in the United States in 2025Insulet is listed alongside Dexcom, Boston Scientific, Stryker, Abbott, and iRhythm.